On June 22, 2022, Aitingwei (Tadalafil Tablets), a drug developed by Shandong Hubble Kisen, a subsidiary of Taienkang, for the treatment of male ED (Erectile Dysfunction) was approved by the State Food and Drug Administration. The registration approval document has become another key andrology product independently developed by Taienkang after the first domestically produced Premature Ejaculation Tablet - Aitingjiu (Dapoxetine Hydrochloride Tablets).

Obtaining the drug registration certificate for Tadalafil Tablets this time is deemed to have passed the consistency evaluation. The company attaches great importance to the drug market for gender health. In addition to the first approved imitation of Dapoxetine Hydrochloride Tablets (trade name: Aitingjiu) and the approved Tadalafil Tablets (Aitingwei), it has also reserved a number of research projects to form a full product pipeline for the treatment of "Premature Ejaculation + Erectile Dysfunction + Reproductive Health", providing patients with more choices and bringing new profit growth points to the company, which is conducive to the sustainable development of the company sexual development.

In the future, Aitingwei will arrange production and launch as soon as possible according to market demand, bringing more medication choices to male patients.